Baicalein attenuates bleomycin-induced pulmonary fibrosis in rats through inhibition of miR-21

Pulmonary Pharmacology and Therapeutics

Volumn 26, Issue 6, 2013, Pages 649-654

  Gao, Yan ^a,b   Lu, Jia ^a   Zhang, Yu ^a   Chen, Yafen ^a   Gu, Zhenlun ^a   Jiang, Xiaogang ^a  

^a SOOCHOW UNIVERSITY   (China)

^b BAOTOU MEDICAL COLLEGE   (China)

Author keywords

Baicalein; Bleomycin; MiR 21; Pulmonary fibrosis; TGF Smad signaling

Indexed keywords

BAICALEIN; BLEOMYCIN; HYDROXYPROLINE; MICRORNA 21; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATTENUATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; HISTOPATHOLOGY; LUNG ALVEOLITIS; LUNG FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; TREATMENT DURATION;

BAICALEIN; BLEOMYCIN; MIR-21; PULMONARY FIBROSIS; TGF-Β/SMAD SIGNALING;

ACTINS; ADMINISTRATION, ORAL; ANIMALS; ANTIOXIDANTS; BLEOMYCIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVANONES; HYDROXYPROLINE; MALE; MICRORNAS; PULMONARY FIBROSIS; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84888009848     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2013.03.006     Document Type: Article

References (30)

1. Gogali A., Wells A.U. New pharmacological strategies for the treatment of pulmonary fibrosis. Ther Adv Respir Dis 2010, 4:353-366.
2. Klingsberg R.C., Mutsaers S.E., Lasky J.A. Current clinical trials for the treatment of idiopathic pulmonary fibrosis. Respirology 2010, 15:19-31.
3. Kliment C.R., Oury T.D. Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis. Free Radic Biol Med 2010, 49:707-717.
4. Broekelmann T.J., Limper A.H., Colby T.V., McDonald J.A. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci U S A 1991, 88:6642-6646.
5. Liu G., Friggeri A., Yang Y., Milosevic J., Ding Q., Thannickal V.J., et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. JExp Med 2010, 207:1589-1597.
6. Pandit K.V., Milosevic J., Kaminski N. MicroRNAs in idiopathic pulmonary fibrosis. Transl Res 2011, 157:191-199.
7. Xiao J., Meng X.M., Huang X.R., Chung A.C., Feng Y.L., Hui D.S., et al. miR-29 inhibits bleomycin-induced pulmonary fibrosis in mice. Mol Ther 2012, 20:1251-1260.
8. Datta A., Scotton C.J., Chambers R.C. Novel therapeutic approaches for pulmonary fibrosis. Br J Pharmacol 2011, 163:141-172.
9. Hsieh C.J., Hall K., Ha T., Li C., Krishnaswamy G., Chi D.S. Baicalein inhibits IL-1beta- and TNF-alpha-induced inflammatory cytokine production from human mast cells via regulation of the NF-kappaB pathway. Clin Mol Allergy 2007, 5:5.
10. Lin Y.L., Lin R.J., Shen K.P., Dai Z.K., Chen I.J., Wu J.R., et al. Baicalein, isolated from Scutellaria baicalensis, protects against endothelin-1-induced pulmonary artery smooth muscle cell proliferation via inhibition of TRPC1 channel expression. JEthnopharmacol 2011, 138:373-381.
11. Choi J.H., Choi A.Y., Yoon H., Choe W., Yoon K.S., Ha J., et al. Baicalein protects HT22 murine hippocampal neuronal cells against endoplasmic reticulum stress-induced apoptosis through inhibition of reactive oxygen species production and CHOP induction. Exp Mol Med 2010, 42:811-822.
12. Lin H.Y., Shen S.C., Lin C.W., Yang L.Y., Chen Y.C. Baicalein inhibition of hydrogen peroxide-induced apoptosis via ROS-dependent heme oxygenase 1 gene expression. Biochim Biophys Acta 2007, 1773:1073-1086.
13. Lin Y.T., Yang J.S., Lin H.J., Tan T.W., Tang N.Y., Chaing J.H., et al. Baicalein induces apoptosis in SCC-4 human tongue cancer cells via a Ca2+-dependent mitochondrial pathway. InVivo 2007, 21:1053-1058.
14. Takahashi H., Chen M.C., Pham H., Angst E., King J.C., Park J., et al. Baicalein, a component of Scutellaria baicalensis, induces apoptosis by Mcl-1 down-regulation in human pancreatic cancer cells. Biochim Biophys Acta 2011, 1813:1465-1474.
15. Sun H., Che Q.M., Zhao X., Pu X.P. Antifibrotic effects of chronic baicalein administration in a CCl4 liver fibrosis model in rats. Eur J Pharmacol 2010, 631:53-60.
16. Kong E.K., Yu S., Sanderson J.E., Chen K.B., Huang Y., Yu C.M. Anovel anti-fibrotic agent, baicalein, for the treatment of myocardial fibrosis in spontaneously hypertensive rats. Eur J Pharmacol 2011, 658:175-181.
17. Moeller A., Ask K., Warburton D., Gauldie J., Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?. Int J Biochem Cell Biol 2008, 40:362-382.
18. Xu P.B., Mao Y.F., Meng H.B., Tian Y.P., Deng X.M. STY39, a novel alpha-melanocyte-stimulating hormone analogue, attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice. Shock 2011, 35:308-314.
19. Hubner R.H., Gitter W., El Mokhtari N.E., Mathiak M., Both M., Bolte H., et al. Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques 2008, 44:507-511. 514-7.
20. Chen C.Y., Peng W.H., Wu L.C., Wu C.C., Hsu S.L. Luteolin ameliorates experimental lung fibrosis both invivo and invitro: implications for therapy of lung fibrosis. JAgric Food Chem 2010, 58:11653-11661.
21. Li P., Gao J., Huang Y., Xu D.J., Li J., Liu Y., et al. Antifibrosis effects of total glucosides of Danggui-Buxue-Tang in a rat model of bleomycin-induced pulmonary fibrosis. JEthnopharmacol 2011, 136:21-26.
22. Margaritopoulos G.A., Romagnoli M., Poletti V., Siafakas N.M., Wells A.U., Antoniou K.M. Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis. Eur Respir Rev 2012, 21:48-56.
23. O'Connell O.J., Kennedy M.P., Henry M.T. Idiopathic pulmonary fibrosis: treatment update. Adv Ther 2011, 28:986-999.
24. Mendell J.T., Olson E.N. MicroRNAs in stress signaling and human disease. Cell 2012, 148:1172-1187.
25. Samah M., El-Aidy Ael R., Tawfik M.K., Ewais M.M. Evaluation of the antifibrotic effect of fenofibrate and rosiglitazone on bleomycin-induced pulmonary fibrosis in rats. Eur J Pharmacol 2012, 689:186-193.
26. Zhao L., Wang X., Chang Q., Xu J., Huang Y., Guo Q., et al. Neferine, a bisbenzylisoquinline alkaloid attenuates bleomycin-induced pulmonary fibrosis. Eur J Pharmacol 2010, 627:304-312.
27. Oku H., Shimizu T., Kawabata T., Nagira M., Hikita I., Ueyama A., et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 2008, 590:400-408.
28. Meng X.M., Huang X.R., Chung A.C., Qin W., Shao X., Igarashi P., et al. Smad2 protects against TGF-beta/Smad3-mediated renal fibrosis. JAm Soc Nephrol 2010, 21:1477-1487.
29. Kolosova I., Nethery D., Kern J.A. Role of Smad2/3 and p38 MAP kinase in TGF-beta1-induced epithelial-mesenchymal transition of pulmonary epithelial cells. JCell Physiol 2011, 226:1248-1254.
30. Yan X., Liu Z., Chen Y. Regulation of TGF-beta signaling by Smad7. Acta Biochim Biophys Sin (Shanghai) 2009, 41:263-272.